Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04498247 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 1
- Development phase
- 263
- Enrollment target
NCT04498247 is a Phase 1 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 263 participants.
The verdict
NCT04498247, a Phase 1 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 263 participants
- Enrollment target
Study Summary
The primary objective of this early Phase 1/2 study is to identify the V591 dose that achieves the target immune response in humans based on preclinical or early clinical data.
Interventions
- OTHER Placebo
- BIOLOGICAL V591
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2020-08-27 |
| Est. Completion | 2021-03-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04498247
The ClinicalTrials.gov registry entry for NCT04498247 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04498247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04498247 about?
NCT04498247 is a clinical study titled "A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)". The primary objective of this early Phase 1/2 study is to identify the V591 dose that achieves the target immune response in humans based on preclinical or early clinical data.
What is the current status of trial NCT04498247?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 263 participants. The study started on 2020-08-27. Estimated completion is 2021-03-05.
What interventions are being tested in trial NCT04498247?
The interventions under investigation include: Placebo (OTHER), V591 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04498247?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.